Chinese Pharmaceuticals Market will reach $227bn in 2019, new Visiongain data predicts

 
 
vg
vg
LONDON - Nov. 19, 2015 - PRLog -- PHA0063 Press release text for Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025

Chinese pharmaceuticals market will reach $227bn in 2019, new visiongain data predicts

A new report by visiongain predicts the Chinese pharma market will generate overall revenues of $227 billion in 2019. Widespread healthcare reform will help that market to expand, with double-digit annual revenue growth expected from 2015 to 2025. That sales forecast and others appear in Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025, published in August 2015. Visiongain is a business information publisher and consultancy based in London, UK.

China remains an exciting and vital market for pharmaceutical companies. China is already the second biggest pharmaceutical market in the world, just behind the US. Though highly fragmented and still developing, the Chinese medicines market has shown vast opportunities and high revenues. But would this continue after the emerging healthcare reform is finished? How about the government’s intervention in areas such as pharmaceutical pricing and reimbursement? Yes, the Chinese pharma market will continue to expand, visiongain predicts. Developments happening now will change the shape of the Chinese market from 2015 to 2025. The purpose of the new study is to explore commercial potentials, assessing trends and opportunities for pharmaceutical companies.

Visiongain’s survey predicts that, from 2015 to 2020, the Chinese biological drugs market will increase its value by almost five times. Also retail pharmacies will become the main drug distribution channel, with over 36% market share by 2025, and anticancer drugs will become the biggest therapeutic segment in China, outperforming the cardiovascular, diabetes and infectious disease segments.

Veselina Gluhova, a pharmaceutical industry analyst in visiongain, said: “Unsurprisingly China managed to secure its position as the second biggest pharmaceutical market in the world. Pharmaceuticals for therapeutic areas such as cancer and diabetes promise booming revenues. Branded drugs and biologics are also very prominent. The government is opening the market for foreign investment even further. Overall, the Chinese pharma market is in strong shape and developing with fast revenue growth. However, policy changes, part of the healthcare reform, may hinder the market’s opportunities, especially those related to pricing and reimbursement.”

Visiongain’s updated report predicts revenues for the overall Chinese pharma market, also showing individual forecasting to 2025 for these therapeutic submarkets:

·         Infectious diseases – antibiotics and other anti-infective products

·         Cancer – applications in oncology, anticancer agents

·         Cardiovascular disorders – with sub-forecasts for hypertension and dyslipidaemia

·         Diabetes therapies

·         Respiratory diseases – with sub-forecasts for COPD and asthma treatments

·         Autoimmune conditions

·         Central nervous system (CNS) disorders – with sub-forecasting for antidepressants

·         Other medical needs (grouped).

That study also gives individual revenue forecasts to 2025 by product class and sales channel:

·         Small-molecule pharmaceuticals – with sub forecasts for original-branded medicines prescription drugs and generics

·         Biological drugs – with sub forecasts for novel biologics, biosimilars and vaccines

·         Traditional Chinese medicines (TCM)

·         Hospitals

·         Retail pharmacies

·         Clinics and other channels

·         Over-the-counter (OTC) products.

The analysis also discusses leading companies – domestic and foreign – in the Chinese market, including ranking of the top 50 Chinese companies according to their pharmaceutical revenues. Domestic organisations covered include these:

·         Guangzhou Pharmaceutical Holdings

·         Shanghai Pharmaceuticals

·         Yunnan Baiyao

·         Harbin Pharmaceuticals

·         Xiuzheng Pharmaceutical Group

·         Sinopharm.

That study also discusses 25 leading multinational companies in China. Firms covered include these:

·         AbbVie

·         Eli Lilly

·         GlaxoSmithKline

·         AstraZeneca

·         Johnson & Johnson

·         Novartis

·         Bayer

·         Pfizer

·         Roche

·         Merck & Co.

Visiongain’s investigation explores market trends, regulatory changes, healthcare reforms and other forces influencing drug sales in China. That work includes interviews with two organisations and other qualitative analysis.

Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 adds to visiongain’s reports on industries and markets in healthcare. Together those studies analyse medicines, medical devices, diagnostics and biotechnology, as well as contract services in research, manufacturing and selling.

Contact
Sara Peerun
***@visiongainglobal.com
End
Source: » Follow
Email:***@visiongainglobal.com Email Verified
Tags:Chinese, Drug, Market
Industry:Business
Location:London City - London, Greater - England
Subject:Reports
Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share